Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK

Background: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but little is known about the epidemiology of these diseases. We used data from a general practice database to provide information on the current incidence of IPF and sarcoidosis in the UK. Methods: Data were extracted for all patients with a diagnosis of IPF or sarcoidosis between 1991 and 2003. The whole population of the database was used to calculate disease incidence stratified by age, sex, region, and time period. Poisson regression was used to compare the incidence between populations and Cox regression was used to compare survival between populations. Results: 920 cases of IPF (mean age 71 years, 62% male) and 1019 cases of sarcoidosis (mean age 47 years, 47% male) were identified. The overall incidence rate per 100 000 person-years was 4.6 for IPF and 5.0 for sarcoidosis. The incidence of IPF increased progressively between 1991 and 2003 (p<0.00001), and was highest in Northern England and Scotland (p<0.0001). The survival of patients with IPF was stable over time. In contrast, the incidence of sarcoidosis was highest in London, West Midlands and Northern Ireland and remained stable over time. Conclusions: The incidence of IPF has more than doubled between 1990 and 2003; this is not due to the ageing of the UK population or an increased ascertainment of milder cases. The incidence of sarcoidosis has not changed during this time period. Our findings suggest that more than 4000 new cases of IPF and 3000 new cases of sarcoidosis are currently diagnosed each year in the UK.

[1]  K. Rabe,et al.  Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study , 2006, The Lancet.

[2]  A. Bourke,et al.  Feasibility study and methodology to create a quality-evaluated database of primary care data. , 2004, Informatics in primary care.

[3]  G. McLennan,et al.  Clinical characteristics of patients in a case control study of sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[4]  J. Samet,et al.  Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. , 2000, American journal of epidemiology.

[5]  R. Hubbard,et al.  Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. , 2000, American journal of respiratory and critical care medicine.

[6]  J. Samet,et al.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts , 1998, Thorax.

[7]  R. Hubbard,et al.  Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. , 1998, Chest.

[8]  M. Iannuzzi,et al.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. , 1997, American journal of epidemiology.

[9]  I. D. Johnston,et al.  Mortality rates from cryptogenic fibrosing alveolitis in seven countries. , 1996, Thorax.

[10]  R. Hubbard,et al.  Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis , 1996, The Lancet.

[11]  W. Black,et al.  The epidemiology of interstitial lung diseases. , 1994, American journal of respiratory and critical care medicine.

[12]  D. Hansell,et al.  Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. , 1994, American journal of respiratory and critical care medicine.

[13]  D. Schwartz,et al.  Determinants of survival in idiopathic pulmonary fibrosis. , 1994, American journal of respiratory and critical care medicine.

[14]  I. D. Johnston,et al.  Rising mortality from cryptogenic fibrosing alveolitis. , 1990, BMJ.

[15]  P. Crean,et al.  High prevalence of familial sarcoidosis in an Irish population. , 1984, Thorax.

[16]  James Crooks,et al.  RESPIRATORY disease. , 2019, Health of the Army. United States. Surgeon-General's Office.